These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 24968263)

  • 1. FGFR2 is amplified in the NCI-H716 colorectal cancer cell line and is required for growth and survival.
    Mathur A; Ware C; Davis L; Gazdar A; Pan BS; Lutterbach B
    PLoS One; 2014; 9(6):e98515. PubMed ID: 24968263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer.
    Verstraete M; Debucquoy A; Gonnissen A; Dok R; Isebaert S; Devos E; McBride W; Haustermans K
    BMC Cancer; 2015 Dec; 15():946. PubMed ID: 26675289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro.
    Cha Y; Kim HP; Lim Y; Han SW; Song SH; Kim TY
    Mol Oncol; 2018 Jun; 12(7):993-1003. PubMed ID: 29573334
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Carter JH; Cottrell CE; McNulty SN; Vigh-Conrad KA; Lamp S; Heusel JW; Duncavage EJ
    Cold Spring Harb Mol Case Stud; 2017 Nov; 3(6):. PubMed ID: 28835367
    [No Abstract]   [Full Text] [Related]  

  • 6. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.
    Kunii K; Davis L; Gorenstein J; Hatch H; Yashiro M; Di Bacco A; Elbi C; Lutterbach B
    Cancer Res; 2008 Apr; 68(7):2340-8. PubMed ID: 18381441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
    Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
    BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired Resistance to FGFR Inhibitor in Diffuse-Type Gastric Cancer through an AKT-Independent PKC-Mediated Phosphorylation of GSK3β.
    Lau WM; Teng E; Huang KK; Tan JW; Das K; Zang Z; Chia T; Teh M; Kono K; Yong WP; Shabbir A; Tay A; Phua NS; Tan P; Chan SL; So JBY
    Mol Cancer Ther; 2018 Jan; 17(1):232-242. PubMed ID: 28978722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
    Chang J; Wang S; Zhang Z; Liu X; Wu Z; Geng R; Ge X; Dai C; Liu R; Zhang Q; Li W; Li J
    Oncotarget; 2015 Feb; 6(4):2009-22. PubMed ID: 25576915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.
    Wickstroem K; Hagemann UB; Kristian A; Ellingsen C; Sommer A; Ellinger-Ziegelbauer H; Wirnitzer U; Hagelin EM; Larsen A; Smeets R; Bjerke RM; Karlsson J; Ryan OB; Wengner AM; Linden L; Mumberg D; Cuthbertson AS
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):410-422. PubMed ID: 31255687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
    Pearson A; Smyth E; Babina IS; Herrera-Abreu MT; Tarazona N; Peckitt C; Kilgour E; Smith NR; Geh C; Rooney C; Cutts R; Campbell J; Ning J; Fenwick K; Swain A; Brown G; Chua S; Thomas A; Johnston SRD; Ajaz M; Sumpter K; Gillbanks A; Watkins D; Chau I; Popat S; Cunningham D; Turner NC
    Cancer Discov; 2016 Aug; 6(8):838-851. PubMed ID: 27179038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AZD-4547 exerts potent cytostatic and cytotoxic activities against fibroblast growth factor receptor (FGFR)-expressing colorectal cancer cells.
    Yao TJ; Zhu JH; Peng DF; Cui Z; Zhang C; Lu PH
    Tumour Biol; 2015 Jul; 36(7):5641-8. PubMed ID: 25691251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2
    Packer LM; Geng X; Bonazzi VF; Ju RJ; Mahon CE; Cummings MC; Stephenson SA; Pollock PM
    Mol Cancer Ther; 2017 Apr; 16(4):637-648. PubMed ID: 28119489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
    Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
    Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR2 Promotes Gastric Cancer Progression by Inhibiting the Expression of Thrombospondin4 via PI3K-Akt-Mtor Pathway.
    Huang T; Liu D; Wang Y; Li P; Sun L; Xiong H; Dai Y; Zou M; Yuan X; Qiu H
    Cell Physiol Biochem; 2018; 50(4):1332-1345. PubMed ID: 30355943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification.
    Kim ST; Jang HL; Lee SJ; Lee J; Choi YL; Kim KM; Cho J; Park SH; Park YS; Lim HY; Yashiro M; Kang WK; Park JO
    Mol Cancer Ther; 2014 Nov; 13(11):2527-36. PubMed ID: 25249557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.
    Bai A; Meetze K; Vo NY; Kollipara S; Mazsa EK; Winston WM; Weiler S; Poling LL; Chen T; Ismail NS; Jiang J; Lerner L; Gyuris J; Weng Z
    Cancer Res; 2010 Oct; 70(19):7630-9. PubMed ID: 20709759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
    Li P; Huang T; Zou Q; Liu D; Wang Y; Tan X; Wei Y; Qiu H
    J Immunol; 2019 May; 202(10):3065-3075. PubMed ID: 30979816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SNORD126 promotes HCC and CRC cell growth by activating the PI3K-AKT pathway through FGFR2.
    Fang X; Yang D; Luo H; Wu S; Dong W; Xiao J; Yuan S; Ni A; Zhang KJ; Liu XY; Chu L
    J Mol Cell Biol; 2017 Jun; 9(3):243-255. PubMed ID: 27913571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ponatinib inhibits growth of patient-derived xenograft of cholangiocarcinoma expressing FGFR2-CCDC6 fusion protein in nude mice].
    Wu T; Jiang X; Xu B; Wang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Oct; 40(10):1448-1456. PubMed ID: 33118510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.